• Record: found
  • Abstract: found
  • Article: not found

Modes of resistance to anti-angiogenic therapy.

Nature reviews. Cancer

Angiogenesis Inhibitors, physiology, drug effects, Vascular Endothelial Growth Factors, Signal Transduction, pathology, etiology, drug therapy, Neovascularization, Pathologic, blood supply, Neoplasms, Humans, Drug Resistance, Neoplasm, therapeutic use, pharmacology

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signalling pathways are affording demonstrable therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers. However, in both preclinical and clinical settings, the benefits are at best transitory and are followed by a restoration of tumour growth and progression. Emerging data support a proposition that two modes of unconventional resistance underlie such results: evasive resistance, an adaptation to circumvent the specific angiogenic blockade; and intrinsic or pre-existing indifference. Multiple mechanisms can be invoked in different tumour contexts to manifest both evasive and intrinsic resistance, motivating assessment of their prevalence and importance and in turn the design of pharmacological strategies that confer enduring anti-angiogenic therapies.

      Related collections

      Author and article information



      Comment on this article